

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

SIDELMAN, Zvi

Serial No.: ~~09/924,12T~~

09/942121

Filed: August 30, 2001

For: CASEIN DERIVED PEPTIDES  
AND USES THEREOF IN THERAPY

Examiner: Samuel W. Liu, Ph.D.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

1. **Introduction**  
 2. **Background**  
 3. **Methodology**  
 4. **Results**  
 5. **Discussion**  
 6. **Conclusion**  
 7. **References**  
 8. **Appendix**  
 9. **Tables**  
 10. **Figures**  
 11. **Supplementary Materials**  
 12. **Notes**  
 13. **Abbreviations**  
 14. **Conflicts of Interest**  
 15. **Acknowledgments**  
 16. **Author Contributions**  
 17. **Funding**  
 18. **Data Availability Statement**  
 19. **References**  
 20. **Appendix**  
 21. **Tables**  
 22. **Figures**  
 23. **Supplementary Materials**  
 24. **Notes**  
 25. **Abbreviations**  
 26. **Conflicts of Interest**  
 27. **Acknowledgments**  
 28. **Author Contributions**  
 29. **Funding**  
 30. **Data Availability Statement**  
 31. **References**  
 32. **Appendix**  
 33. **Tables**  
 34. **Figures**  
 35. **Supplementary Materials**  
 36. **Notes**  
 37. **Abbreviations**  
 38. **Conflicts of Interest**  
 39. **Acknowledgments**  
 40. **Author Contributions**  
 41. **Funding**  
 42. **Data Availability Statement**  
 43. **References**  
 44. **Appendix**  
 45. **Tables**  
 46. **Figures**  
 47. **Supplementary Materials**  
 48. **Notes**  
 49. **Abbreviations**  
 50. **Conflicts of Interest**  
 51. **Acknowledgments**  
 52. **Author Contributions**  
 53. **Funding**  
 54. **Data Availability Statement**  
 55. **References**  
 56. **Appendix**  
 57. **Tables**  
 58. **Figures**  
 59. **Supplementary Materials**  
 60. **Notes**  
 61. **Abbreviations**  
 62. **Conflicts of Interest**  
 63. **Acknowledgments**  
 64. **Author Contributions**  
 65. **Funding**  
 66. **Data Availability Statement**  
 67. **References**  
 68. **Appendix**  
 69. **Tables**  
 70. **Figures**  
 71. **Supplementary Materials**  
 72. **Notes**  
 73. **Abbreviations**  
 74. **Conflicts of Interest**  
 75. **Acknowledgments**  
 76. **Author Contributions**  
 77. **Funding**  
 78. **Data Availability Statement**  
 79. **References**  
 80. **Appendix**  
 81. **Tables**  
 82. **Figures**  
 83. **Supplementary Materials**  
 84. **Notes**  
 85. **Abbreviations**  
 86. **Conflicts of Interest**  
 87. **Acknowledgments**  
 88. **Author Contributions**  
 89. **Funding**  
 90. **Data Availability Statement**  
 91. **References**  
 92. **Appendix**  
 93. **Tables**  
 94. **Figures**  
 95. **Supplementary Materials**  
 96. **Notes**  
 97. **Abbreviations**  
 98. **Conflicts of Interest**  
 99. **Acknowledgments**  
 100. **Author Contributions**  
 101. **Funding**  
 102. **Data Availability Statement**  
 103. **References**  
 104. **Appendix**  
 105. **Tables**  
 106. **Figures**  
 107. **Supplementary Materials**  
 108. **Notes**  
 109. **Abbreviations**  
 110. **Conflicts of Interest**  
 111. **Acknowledgments**  
 112. **Author Contributions**  
 113. **Funding**  
 114. **Data Availability Statement**  
 115. **References**  
 116. **Appendix**  
 117. **Tables**  
 118. **Figures**  
 119. **Supplementary Materials**  
 120. **Notes**  
 121. **Abbreviations**  
 122. **Conflicts of Interest**  
 123. **Acknowledgments**  
 124. **Author Contributions**  
 125. **Funding**  
 126. **Data Availability Statement**  
 127. **References**  
 128. **Appendix**  
 129. **Tables**  
 130. **Figures**  
 131. **Supplementary Materials**  
 132. **Notes**  
 133. **Abbreviations**  
 134. **Conflicts of Interest**  
 135. **Acknowledgments**  
 136. **Author Contributions**  
 137. **Funding**  
 138. **Data Availability Statement**  
 139. **References**  
 140. **Appendix**  
 141. **Tables**  
 142. **Figures**  
 143. **Supplementary Materials**  
 144. **Notes**  
 145. **Abbreviations**  
 146. **Conflicts of Interest**  
 147. **Acknowledgments**  
 148. **Author Contributions**  
 149. **Funding**  
 150. **Data Availability Statement**  
 151. **References**  
 152. **Appendix**  
 153. **Tables**  
 154. **Figures**  
 155. **Supplementary Materials**  
 156. **Notes**  
 157. **Abbreviations**  
 158. **Conflicts of Interest**  
 159. **Acknowledgments**  
 160. **Author Contributions**  
 161. **Funding**  
 162. **Data Availability Statement**  
 163. **References**  
 164. **Appendix**  
 165. **Tables**  
 166. **Figures**  
 167. **Supplementary Materials**  
 168. **Notes**  
 169. **Abbreviations**  
 170. **Conflicts of Interest**  
 171. **Acknowledgments**  
 172. **Author Contributions**  
 173. **Funding**  
 174. **Data Availability Statement**  
 175. **References**  
 176. **Appendix**  
 177. **Tables**  
 178. **Figures**  
 179. **Supplementary Materials**  
 180. **Notes**  
 181. **Abbreviations**  
 182. **Conflicts of Interest**  
 183. **Acknowledgments**  
 184. **Author Contributions**  
 185. **Funding**  
 186. **Data Availability Statement**  
 187. **References**  
 188. **Appendix**  
 189. **Tables**  
 190. **Figures**  
 191. **Supplementary Materials**  
 192. **Notes**  
 193. **Abbreviations**  
 194. **Conflicts of Interest**  
 195. **Acknowledgments**  
 196. **Author Contributions**  
 197. **Funding**  
 198. **Data Availability Statement**  
 199. **References**  
 200. **Appendix**  
 201. **Tables**  
 202. **Figures**  
 203. **Supplementary Materials**  
 204. **Notes**  
 205. **Abbreviations**  
 206. **Conflicts of Interest**  
 207. **Acknowledgments**  
 208. **Author Contributions**  
 209. **Funding**  
 210. **Data Availability Statement**  
 211. **References**  
 212. **Appendix**  
 213. **Tables**  
 214. **Figures**  
 215. **Supplementary Materials**  
 216. **Notes**  
 217. **Abbreviations**  
 218. **Conflicts of Interest**  
 219. **Acknowledgments**  
 220. **Author Contributions**  
 221. **Funding**  
 222. **Data Availability Statement**  
 223. **References**  
 224. **Appendix**  
 225. **Tables**  
 226. **Figures**  
 227. **Supplementary Materials**  
 228. **Notes**  
 229. **Abbreviations**  
 230. **Conflicts of Interest**  
 231. **Acknowledgments**  
 232. **Author Contributions**  
 233. **Funding**  
 234. **Data Availability Statement**  
 235. **References**  
 236. **Appendix**  
 237. **Tables**  
 238. **Figures**  
 239. **Supplementary Materials**  
 240. **Notes**  
 241. **Abbreviations**  
 242. **Conflicts of Interest**  
 243. **Acknowledgments**  
 244. **Author Contributions**  
 245. **Funding**  
 246. **Data Availability Statement**  
 24

Group Art Unit: 1653

Attorney **T**  
Docket: 01/22453

**RECEIVED**  
**CENTRAL FAX CENTER**  
**FEB 02 2005**

RECEIVED  
FEB 10 2005  
Technology Center 2600  
453

**BY FAX: (703) 872-9306 – 6 PAGES**

Sir:

In a telephone call with the Examiner on February 2, 2005, the Examiner indicated that the Election Applicant filed was never received by the Group.

Attached herewith is the Election Response filed on September 30, along with the Extension of Time authorization (the document listing the Credit Card number is not provided, for security reasons), and the stamped proof that the Election was received by the USPTO on September 30, 2004.

Entry and processing of the application in light of the above filing is deemed to be in order.

Respectfully submitted,

*Ed. Shuler*

Sol Sheinbein  
Registration No. 25,457

Date: February 2, 2005

APPLICANT : SIDELMAN  
DOCKET NO. : 01/22453  
SERIAL NO. : 09/942,121  
FILED : 30 August 2001  
FOR : Casein Derived Peptides And Uses Thereof In Therapy

RECEIVED  
FEB 10 2005  
Technology Center 2600

Receipt of the following papers is acknowledged by the U.S. Patent & Trademark Office as evidenced by the Mail Room Stamp:

**ELECTION  
FEE FOR EXTENSION OF TIME**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICERECEIVED  
CENTRAL FAX CENTERRECEIVED  
FEB 09 2005

FEB 10 2005

Technology Center 2600

In re Application of:

SIDELMAN, Zvi

Serial No.:

09/924,121

09/942/21

Filed:

August 30, 2001

For:

CASEIN DERIVED PEPTIDES  
AND USES THEREOF IN THERAPY

Examiner:

Samuel W. Liu, Ph.D.

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Group Art Unit: 1653

Attorney

Docket: 01/22453

PETITION AND FEE FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)

Sir:

(1) This is a petition for an extension of time to respond to the Office Action mailed July 1, 2004, for a period of two months.

(2) Applicant is a:  
X small entity     other than small entity

(3) Extension	Fee for small entity <u>small entity</u>	Fee for other than <u>small entity</u>
<u>    </u> one month	\$ 55	\$ 110
<u>X</u> two months	\$ 210	\$ 420
<u>    </u> three months	\$ 475	\$ 950
<u>    </u> four months	\$ 740	\$ 1480
<u>    </u> five months	\$1005	\$ 2010

(4) An amendment X is filed herewith  
     has been filed

(5) Authorization to charge the above extension fee of \$210 to the Credit Card number listed on the attached Credit Card Payment Form PTO-2038 is attached herewith. In the event additional fees are required, please charge these additional fees to Deposit Account 50-1407. In the unlikely event payment by the Credit Card issuer is refused, please charge the extension fee of \$210 to Deposit Account 50-1407.

Respectfully submitted,



Sol Sheinbein

Registration No. 25,457

Date: September 28, 2004